Paul R Vigano

10% owner Paul Vigano sells 7,000,000 shares (96.5% of holdings) at $6.24 for $43,680,000

Paul Vigano, a 10% beneficial owner of Aveanna Healthcare, executed 3 separate sales totaling 7,000,000 shares for $43,680,000 on 2026-06-03, reducing his stake from 7,252,899 shares to 252,899 shares. This represents a near-complete liquidation of his position at $6.24 per share, when the stock currently trades at $6.66. Vigano's cross-ticker track record shows his 8 prior sells averaged poorly-timed exits (37.50% well-timed rate), though at AVAH specifically, 3 of 5 prior sales were well-timed at the 90-day mark. The company trades at a P/E of 6.00 with strong 20.2% annual revenue growth, $647.9M in quarterly revenue, and $41.7M in net income, yet Vigano's divestment of virtually his entire stake signals a material shift in his ownership position regardless of valuation metrics.

10% owner VIGANO PAUL R sold 1,500,000 shares at $9.00 for $13,500,000.00 on 2025-10-24, reducing holdings 80.5%.

Paul R. Vigano, a 10% owner of Aveanna Healthcare, filed three separate sell transactions totaling 1,500,000 shares (1.50M shares) at $9.00 on 2025-10-24 for $13,500,000.00, reducing his holdings from 1,862,746 shares (1.86M shares) to 362,746 shares (362.7K shares) — an 80.5% reduction in his position. The timing is notable given that three prior sales at the same ticker occurred on 2025-10-21 (outcome not yet measurable), followed by two earlier measured sales: one on 2025-06-10 (30d -18.6%, 90d +58.8%) and one on 2025-05-19 (30d -10.6%, 90d +32.1%), showing a pattern where the stock subsequently recovered in both measurable instances. The current price of $9.81 sits 4.5% below the 52-week high of $10.27 but reflects strong 90-day momentum of +145.9%, and the company carries a P/E of 109.00 while trading at a $2.0B market cap despite full-year net income being negative. This substantial liquidation by a founding-level shareholder warrants investor scrutiny into his rationale, particularly given the magnitude of the stake reduction and the company's elevated valuation relative to profitability.

10% Owner Vigano sold 10,000,000 shares for $90,000,000 at $9.00, reducing stake 96.3% to 386.3K shares

Vigano, holding 10% of Aveanna Healthcare, executed 3 separate sales totaling 10,000,000 shares for $90,000,000.00 at $9.00 on 2025-10-21, leaving just 386.3K shares post-transaction. The stock currently trades at $9.12, near its 52-week high of $10.27, and has gained 8.7% in 30 days and 130.3% in 90 days. Vigano's prior 2 sales at this ticker (2025-06-10 and 2025-05-19) each showed positive 90-day returns (+58.8% and +32.1%), meaning the stock rose after each prior sale—a 0% well-timed rate at this ticker. This near-total liquidation of a major founder stake differs sharply from that pattern of moderate partial reductions, and occurs as the company reports a P/E of 101.33 with annual revenue growth of 6.8% but full-year net income that was negative.

10% owner VIGANO PAUL R sold 750,000 shares (750.0K) of AVAH at $5.20 on 2025-06-10; still holds 28.89M shares

VIGANO PAUL R, a 10% shareholder, sold 750,000 shares for $3,900,000.00 on 2025-06-10 at $5.20 per share, reducing his position by 2.5% to 28.89M shares. The transaction occurred in a context where the stock currently trades at $5.08, down 13.3% over 30 days and down 15.3% from its 52-week high of $6.00. The company generated $559.2M in quarterly revenue with $5.2M in net income but was unprofitable over its most recent full fiscal year; the elevated P/E of 169.33 reflects the slim profitability margins. His prior transaction at this ticker (a sell on 2025-05-19) lacks measurable 90-day outcomes, offering no evidence of pattern timing accuracy at this name.

10% owner Paul Vigano sells 1,560,700 shares of AVAH at $5.36; retains 29,640,756 shares post-sale

Paul Vigano, a 10% owner of Aveanna Healthcare, sold 1,560,700 shares (1.56M shares) at $5.36 on 2025-05-19, representing a -5.0% reduction from his pre-transaction holdings of 31,201,456 shares (31.20M shares). The sale valued at $8,365,352.00 ($8.4M) occurs in a context where the company is fundamentally challenged: it reported full-year net income in the negative and a quarterly net income of only $5,193,000.00 ($5.2M) against revenue of $559,224,000.00 ($559.2M). The P/E ratio of 183.00 reflects earnings scarcity. While the 30-day price change of +30.1% and proximity to the 52-week high of $6.00 (the current price of $5.49 being -8.5% from that high) might suggest recent strength, the company's profitability profile remains structurally weak, and Vigano's discretionary sale of over 1.5 million shares warrants investor attention to execution risks in the healthcare services business.